230 related articles for article (PubMed ID: 16844446)
1. Neuroendocrine differentiation in prostate cancer.
Shariff AH; Ather MH
Urology; 2006 Jul; 68(1):2-8. PubMed ID: 16844446
[No Abstract] [Full Text] [Related]
2. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
3. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
[TBL] [Abstract][Full Text] [Related]
4. [Endocrine differentiated prostate cancer. Histology and immunohistochemistry].
Helpap B; Oehler U; Bollmann R
Pathologe; 1990 Jan; 11(1):18-24. PubMed ID: 1690418
[No Abstract] [Full Text] [Related]
5. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
8. Divergent neuroendocrine differentiation in prostatic carcinoma.
di Sant' Agnese PA
Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
[TBL] [Abstract][Full Text] [Related]
9. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2.
Diaz M; Abdul M; Hoosein N
Prostate Suppl; 1998; 8():32-6. PubMed ID: 9690661
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
Cohen RJ; Glezerson G; Haffejee Z
Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
Abrahamsson PA; Cockett AT; di Sant'Agnese PA
Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
14. [Neuroendocrine tumors of the prostate].
Bours AF; Jorion JL; Donnay M; Ledent G; Van Ruyssevelt C
Acta Urol Belg; 1993 Sep; 61(3):13-6. PubMed ID: 8256680
[TBL] [Abstract][Full Text] [Related]
15. Receptors for BPH growth factors are located in some neuroendocrine cells.
Iwamura M; Koshiba K; Cockett AT
Prostate Suppl; 1998; 8():14-7. PubMed ID: 9690658
[TBL] [Abstract][Full Text] [Related]
16. [Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma].
Li GZ; Zeng L; Zhang J; Yuan YM; Yang XY; Wang JH; Na YQ; Guo YL
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):493-5. PubMed ID: 14575578
[TBL] [Abstract][Full Text] [Related]
17. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
18. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker".
Abrahamsson PA; Falkmer S; Fält K; Grimelius L
Pathol Res Pract; 1989 Sep; 185(3):373-80. PubMed ID: 2813190
[TBL] [Abstract][Full Text] [Related]
19. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.
Grobholz R; Bohrer MH; Siegsmund M; Jünemann KP; Bleyl U; Woenckhaus M
Pathol Res Pract; 2000; 196(5):277-84. PubMed ID: 10834383
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
